These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 38003976

  • 1. A Review of the Resistance Mechanisms for β-Lactams, Macrolides and Fluoroquinolones among Streptococcus pneumoniae.
    Zahari NIN, Engku Abd Rahman ENS, Irekeola AA, Ahmed N, Rabaan AA, Alotaibi J, Alqahtani SA, Halawi MY, Alamri IA, Almogbel MS, Alfaraj AH, Ibrahim FA, Almaghaslah M, Alissa M, Yean CY.
    Medicina (Kaunas); 2023 Oct 31; 59(11):. PubMed ID: 38003976
    [Abstract] [Full Text] [Related]

  • 2. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
    File TM.
    J Manag Care Pharm; 2009 Mar 31; 15(2 Suppl):S5-11. PubMed ID: 19236135
    [Abstract] [Full Text] [Related]

  • 3. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A, Sayıner A, Çelenk B, Şakar Coşkun A, Kılınç O, Hazar A, Aktaş Samur A, Taşbakan S, Waterer GW, Havlucu Y, Kılıç Ö, Tokgöz F, Bilge U.
    Turk J Med Sci; 2018 Aug 16; 48(4):730-736. PubMed ID: 30119147
    [Abstract] [Full Text] [Related]

  • 4. Penicillin resistance in pneumococcal pneumonia. Antibiotics with low resistance potential are effective and pose less risk.
    Cunha BA.
    Postgrad Med; 2003 Jan 16; 113(1):42-4, 47-8, 52-4. PubMed ID: 12545592
    [Abstract] [Full Text] [Related]

  • 5. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides.
    Cornick JE, Bentley SD.
    Microbes Infect; 2012 Jul 16; 14(7-8):573-83. PubMed ID: 22342898
    [Abstract] [Full Text] [Related]

  • 6. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May 16; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 7. Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae.
    Drago L, Nicola L, Rodighiero V, Larosa M, Mattina R, De Vecchi E.
    J Antimicrob Chemother; 2011 Apr 16; 66(4):845-9. PubMed ID: 21393187
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications.
    Cherazard R, Epstein M, Doan TL, Salim T, Bharti S, Smith MA.
    Am J Ther; 2017 May 16; 24(3):e361-e369. PubMed ID: 28430673
    [Abstract] [Full Text] [Related]

  • 9. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A, Cilloniz C, Martin-Loeches I, Ranzani OT, Gabarrus A, Bueno L, Garcia-Vidal C, Ferrer M, Niederman MS, Torres A.
    Chest; 2019 Apr 16; 155(4):795-804. PubMed ID: 30471269
    [Abstract] [Full Text] [Related]

  • 10. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
    Yayan J.
    Drug Des Devel Ther; 2014 Apr 16; 8():1733-43. PubMed ID: 25336917
    [Abstract] [Full Text] [Related]

  • 11. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2002 Sep 16; 44(1):77-84. PubMed ID: 12376036
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of beta-lactams, macrolides, telithromycin, and fluoroquinolones against clinical isolates of Streptococcus pneumoniae: correlation between drug resistance and genetic characteristics.
    Yamaguchi T, Hashikita G, Takahashi S, Itabashi A, Yamazaki T, Maesaki S.
    J Infect Chemother; 2005 Oct 16; 11(5):262-4. PubMed ID: 16258826
    [Abstract] [Full Text] [Related]

  • 13. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia.
    Olson G, Davis AM.
    JAMA; 2020 Mar 03; 323(9):885-886. PubMed ID: 32027358
    [No Abstract] [Full Text] [Related]

  • 14. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A, Shasha D, Paul M.
    Int J Antimicrob Agents; 2015 Sep 03; 46(3):242-8. PubMed ID: 26092096
    [Abstract] [Full Text] [Related]

  • 15. Role of beta-lactam agents in the treatment of community-acquired pneumonia.
    Garau J.
    Eur J Clin Microbiol Infect Dis; 2005 Feb 03; 24(2):83-99. PubMed ID: 15696306
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN, Fritsche TR, Sader HS.
    Diagn Microbiol Infect Dis; 2005 Jun 03; 52(2):129-33. PubMed ID: 15964501
    [Abstract] [Full Text] [Related]

  • 17. Elderly patients with community-acquired pneumonia: optimal treatment strategies.
    Thiem U, Heppner HJ, Pientka L.
    Drugs Aging; 2011 Jul 01; 28(7):519-37. PubMed ID: 21721597
    [Abstract] [Full Text] [Related]

  • 18. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
    Oosterheert JJ, Bonten MJ, Hak E, Schneider MM, Hoepelman IM.
    J Antimicrob Chemother; 2003 Oct 01; 52(4):555-63. PubMed ID: 12972448
    [Abstract] [Full Text] [Related]

  • 19. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT, Arfstrom RJ, Mihalovic SW, Dababneh AS, Varatharaj Palraj BR, Dierkhising RA, Mara KC, Lessard SR.
    Am J Ther; 2020 Oct 01; 27(2):e177-e182. PubMed ID: 30418221
    [Abstract] [Full Text] [Related]

  • 20. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG.
    Arch Intern Med; 2000 May 22; 160(10):1399-408. PubMed ID: 10826451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.